<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">DIJ</journal-id><journal-id journal-id-type="hwp">spdij</journal-id><journal-title>Therapeutic Innovation &amp; Regulatory Science</journal-title><issn pub-type="ppub">2168-4790</issn><issn pub-type="epub">2164-9200</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1177/2168479013486270</article-id><article-id pub-id-type="publisher-id">10.1177_2168479013486270</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials</subject></subj-group></article-categories><title-group><article-title>Analysis Sets and Inference in Clinical Trials</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rosenkranz</surname><given-names>Gerd K.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1-2168479013486270">1</xref><xref ref-type="corresp" rid="corresp1-2168479013486270"/></contrib></contrib-group><aff id="aff1-2168479013486270"><label>1</label>Novartis Pharma AG, Basel, Switzerland</aff><author-notes><corresp id="corresp1-2168479013486270">Gerd K. Rosenkranz, Novartis Pharma AG, Novartis Campus, Basel, CH-4002, Switzerland. Email: <email>gerd.rosenkranz@novartis.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>7</month><year>2013</year></pub-date><volume>47</volume><issue>4</issue><fpage>455</fpage><lpage>459</lpage><history><date date-type="received"><day>25</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>© The Author(s) 2013</copyright-statement><copyright-year>2013</copyright-year><copyright-holder content-type="other">Drug Information Association</copyright-holder></permissions><abstract><p>The debate about what constitutes a valid analysis of clinical trial data is longstanding. While the intention-to-treat (ITT) principle seems to be widely accepted in the context of controlled clinical trials aiming to show superiority of an experimental treatment over a control, the best choice for a noninferiority trial is still under discussion. In this article, it is argued that the definition of analysis sets and the purpose of ITT and per-protocol analyses proposed in the International Conference on Harmonisation biostatistics guideline E9 should be revised to allow for more appropriate analyses, given that statistical methodology has been developed since the guideline was issued.</p></abstract><kwd-group><kwd>analysis sets</kwd><kwd>compliance</kwd><kwd>efficacy</kwd><kwd>effectiveness</kwd></kwd-group></article-meta></front><body><sec id="section1-2168479013486270"><title>Introduction</title><p>The debate about what constitutes a valid analysis of clinical trial data is longstanding. While the intention-to-treat (ITT) principle seems to be widely accepted in the context of controlled clinical trials aiming to show superiority of an experimental treatment over a control, the best choice for a noninferiority trial is still under discussion.<sup><xref ref-type="bibr" rid="bibr1-2168479013486270">1</xref></sup> The International Conference on Harmonisation (ICH) biostatistics guideline E9 attempts to settle the discussion by defining analysis sets and their purpose in the context of clinical trials.<sup><xref ref-type="bibr" rid="bibr2-2168479013486270">2</xref></sup> However, as is shown below, this attempt fails to provide appropriate analyses for the most part. Instead, fallback positions like “conservative analyses” are favored and sensitivity analyses are proposed to check the dependence of the results on the analysis sets used.</p><p>The topic of a valid analysis was touched upon some years before ICH E9 was released in 1998. For example, Sommer and Zeger<sup><xref ref-type="bibr" rid="bibr3-2168479013486270">3</xref></sup> elaborated in 1991 on the analysis of a vitamin A study from an ITT and a per-protocol perspective and proposed a third analysis that more appropriately estimates the effect of the vitamin A intervention on survival. This example is discussed in more detail later in the article.</p><p>Sheiner and Rubin<sup><xref ref-type="bibr" rid="bibr4-2168479013486270">4</xref></sup> argued in 1995 about the role of ITT and per-protocol analyses in determining the effect of treatment over control. In a simplified noncompliance setting, they showed that an inverse probability of compliance weighted ITT analysis provides an unbiased estimator of efficacy—not the per-protocol analysis as one would expect in the first place. The reasoning of these authors is also laid out in more detail below.</p><p>Rubin and coauthors<sup><xref ref-type="bibr" rid="bibr5-2168479013486270">5</xref>,<xref ref-type="bibr" rid="bibr6-2168479013486270">6</xref></sup> generalized and formalized the approach in the 1995 paper by introducing the concept of principal stratification to allow for valid analyses for strata defined on postrandomization criteria. Other authors have developed methods to handle noncompliance by structural mean models.<sup><xref ref-type="bibr" rid="bibr7-2168479013486270">7</xref>,<xref ref-type="bibr" rid="bibr8-2168479013486270">8</xref></sup> Kenward and Rosenkranz<sup><xref ref-type="bibr" rid="bibr9-2168479013486270">9</xref></sup> proposed a shared parameter model to account for different degrees of compliance and missing data.</p><sec id="section2-2168479013486270"><title>Definition and Purpose of Analysis Sets</title><p>The analysis set definitions as contained in ICH E9, primarily for the full analysis set (FAS) and the per-protocol set (PPS), are as follows:<disp-quote><p>The term “<italic>full analysis set”</italic> is used to describe the analysis set which is as complete as possible and as close as possible to the intention-to-treat ideal of <italic>including all randomized subjects.</italic></p></disp-quote><disp-quote><p>The <italic>“per protocol”</italic> set of subjects, sometimes described as the “valid cases”, the “efficacy” sample or the “evaluable subjects” sample, defines a subset of the subjects in the full analysis set who are more compliant with the protocol and is characterized by criteria such as the following:</p></disp-quote><list list-type="bullet"><list-item><p>the completion of a certain pre-specified minimal exposure to the treatment regimen;</p></list-item><list-item><p>the availability of measurements of the primary variable(s);</p></list-item><list-item><p>the absence of any major protocol violations including the violation of entry criteria.<sup><xref ref-type="bibr" rid="bibr2-2168479013486270">2</xref></sup></p></list-item></list>Arguments in favor of the FAS as a basis for the primary analysis of a clinical trial are given as well:<list list-type="bullet"><list-item><p>Preservation of the initial randomization in analysis is important in preventing bias and in providing a secure foundation for statistical tests.</p></list-item><list-item><p>In many clinical trials the use of the full analysis set provides a <italic>conservative strategy</italic>.</p></list-item><list-item><p>Under many circumstances it may also provide <italic>estimates of treatment effects</italic> which are more likely to <italic>mirror those observed in subsequent practice</italic>.<sup><xref ref-type="bibr" rid="bibr2-2168479013486270">2</xref></sup></p></list-item></list></p><p>The first statement is a reminder that randomization is the basis for inference and should therefore be respected. The meaning of the second statement is not so obvious. In case of full compliance with the protocol, there would be little debate about the use of the FAS for the analysis. In case of lack of compliance or improper conduct of a study, the inclusion of all data in the analysis may tend to reduce the treatment effect estimator since the groups to be compared may look more similar. The latter will likely not be a preferable strategy for noninferiority trials as made explicit in ICH E9:<list list-type="bullet"><list-item><p>The equivalence (or non-inferiority) trial is not conservative in nature, so that many flaws in the design or conduct of the trial tend to bias the results towards a conclusion of equivalence.<sup><xref ref-type="bibr" rid="bibr2-2168479013486270">2</xref></sup></p></list-item></list></p><p>The statement that an ITT analysis provides an estimator of a treatment effect that better reflects the effect observed in subsequent practice seems to assume that the degree of noncompliance in a clinical study is similar to a real-world setting and hence an estimator as obtained from such an analysis is more realistic than one obtained from a subset of patients with higher degree of adherence to the protocol.</p><p>The guideline further recommends conducting an analysis using both the FAS and the PPS for the following reasons<sup><xref ref-type="bibr" rid="bibr2-2168479013486270">2</xref></sup>:<list list-type="bullet"><list-item><p>In general, it is advantageous to demonstrate a <italic>lack of sensitivity</italic> of the principal trial results to alternative choices of the set of subjects analyzed.</p></list-item><list-item><p>In confirmatory trials it is usually appropriate to plan to conduct <italic>both an analysis of the full analysis set and a per protocol analysis</italic>, so that any differences between them can be the subject of explicit discussion and interpretation.</p></list-item></list></p></sec><sec id="section3-2168479013486270"><title>Critique of the ICH E9 Sections on Analysis Sets</title><p>The recommendations given in ICH E9<sup><xref ref-type="bibr" rid="bibr2-2168479013486270">2</xref></sup> in regard to the use of analyses based on FAS and PPS raise some questions.</p><p>It is important to note that although not explicitly stated in the guideline, analyses based on the 2 analysis sets try to answer different questions. An analysis including all patients regardless of compliance allows primarily to estimate the effect of treatment assignment in the situation of a controlled clinical trial. Following Zeger and Sommer<sup><xref ref-type="bibr" rid="bibr3-2168479013486270">3</xref></sup> we call the effect of treatment assignment <italic>effectiveness</italic>. The analysis based on the outcomes of patients adhering to the protocol tries to provide an estimator of the biological treatment efficacy, that is, the <italic>effect of treatment.</italic></p><p>As a first consequence of these considerations, it should not come as a surprise that FAS-and PPS-based analysis will deliver different results as a rule rather than as an exception under lack of compliance. Second, we also argue that in general neither does the FAS analysis provide an estimator of real-world effectiveness nor does the PPS analysis provide an (unbiased) estimator of efficacy.</p><p>There is some agreement that the patient population in clinical trials is not a representative sample of the general patient population.<sup><xref ref-type="bibr" rid="bibr10-2168479013486270">10</xref></sup> Patients who consent to participate in a clinical trial may have different compliance behaviors than do patients who are not willing to participate. The participating centers of a trial are not randomly selected but are chosen based on criteria like performance and quality. Patients in clinical trials are monitored and cared for much more closely than are patients treated outside clinical trials. Since effectiveness depends heavily on compliance, it is questionable to what extent the effectiveness of a therapy as observed in a clinical trial predicts effectiveness in everyday use. For the latter situation, compliance may be even worse than in the trial and hence the effect estimator from the trial would be no longer conservative.</p><p>While the ITT analysis still provides an appropriate estimator of effectiveness in the context of a clinical trial, a per-protocol analysis is generally not able to provide an appropriate estimate of <italic>efficacy</italic> since it does not compare like with like. By considering the compliers to control in one group of patients and compliers to experimental treatment in the other, the resulting populations constitute different selections from populations that have been identically distributed at baseline because of randomization. In fact, the only situation in which a per-protocol analysis would provide a valid but inefficient estimator of efficacy would be a “compliance completely at random” situation. This conclusion questions the fundamental value of a per-protocol analysis since it estimates neither efficacy nor effectiveness appropriately in the presence of noncompliance.</p></sec><sec id="section4-2168479013486270"><title>Estimators of Efficacy Under Lack of Compliance</title><p>Sommer and Zeger<sup><xref ref-type="bibr" rid="bibr3-2168479013486270">3</xref></sup> considered a community-based randomized trial of vitamin A supplementation to reduce mortality among preschool children in rural Indonesia. Deaths were ascertained in a population census 12 months following the baseline census. The data are shown in <xref ref-type="table" rid="table1-2168479013486270">Table 1</xref> stratified by compliance to vitamin A (ie, whether a patient would have taken vitamin A had it been assigned to him). This information is known only from children who were actually assigned to vitamin A and not from those who received no treatment. Patients assigned no treatment are considered compliant since there was no opportunity to obtain vitamin A outside the study. It should be noted that patients assigned to vitamin A but not taking it have a higher mortality rate than the control group as a whole.</p><table-wrap id="table1-2168479013486270" position="float"><label>Table 1.</label><caption><p>Raw data from a community-based randomized trial of vitamin A supplementation to reduce mortality in preschool children.</p></caption><graphic alternate-form-of="table1-2168479013486270" xlink:href="10.1177_2168479013486270-table1.tif"/><table><thead><tr><th/><th colspan="6">Compliant to Vitamin A</th></tr><tr><th/><th colspan="3">Control</th><th colspan="3">Vitamin A</th></tr><tr><th/><th>No</th><th>Yes</th><th>All</th><th>No</th><th>Yes</th><th>All</th></tr></thead><tbody><tr><td>Alive, n</td><td>?</td><td>?</td><td>11,514</td><td>2385</td><td>9663</td><td>12,048</td></tr><tr><td>Dead, n</td><td>?</td><td>?</td><td>74</td><td>34</td><td>12</td><td>46</td></tr><tr><td>Total, n</td><td/><td/><td>11,588</td><td>2419</td><td>9675</td><td>12,094</td></tr><tr><td>Mortality, %</td><td/><td/><td>0.64</td><td>1.41</td><td>0.12</td><td>0.38</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-2168479013486270"><p>Data from Sommer and Zeger.<sup><xref ref-type="bibr" rid="bibr3-2168479013486270">3</xref></sup></p></fn></table-wrap-foot></table-wrap><p>As can be seen from <xref ref-type="table" rid="table1-2168479013486270">Table 1</xref>, an ITT analysis would result in a relative risk of 0.38/0.64 = 0.59. However, since the distribution system used in the trial would not be the method of choice in a subsequent program if vitamin A were proven to reduce mortality, the effectiveness estimated from the trial would not fully inform about the effectiveness in a future prevention program. Therefore, an estimator of efficacy is of interest.</p><table-wrap id="table2-2168479013486270" position="float"><label>Table 2.</label><caption><p>Data from <xref ref-type="table" rid="table1-2168479013486270">Table 1</xref> after estimation of the missing data under vitamin A compliance in the control group.</p></caption><graphic alternate-form-of="table2-2168479013486270" xlink:href="10.1177_2168479013486270-table2.tif"/><table><thead><tr><th/><th colspan="6">Compliant to Vitamin A</th></tr><tr><th/><th colspan="3">Control</th><th colspan="3">Vitamin A</th></tr><tr><th/><th>No</th><th>Yes</th><th>All</th><th>No</th><th>Yes</th><th>All</th></tr></thead><tbody><tr><td>Alive, n</td><td>2285.2</td><td>9228.8</td><td>11,514</td><td>2385</td><td>9663</td><td>12,048</td></tr><tr><td>Dead, n</td><td>32.6</td><td>41.4</td><td>74</td><td>34</td><td>12</td><td>46</td></tr><tr><td>Total, n</td><td>2317.8</td><td>9270.2</td><td>11,588</td><td>2419</td><td>9675</td><td>12,094</td></tr><tr><td>Mortality, %</td><td>1.41</td><td>0.45</td><td>0.64</td><td>1.41</td><td>0.12</td><td>0.38</td></tr></tbody></table></table-wrap><p>A per-protocol analysis comparing vitamin A compliers to control provides a relative risk of 0.12/0.64 = 0.19, suggesting an 80% reduction of mortality by vitamin A for compliers. As said earlier, such an analysis does not compare like with like since it ignores the potential vitamin A noncompliers in the control group had they been assigned vitamin A. A more appropriate analysis can be obtained under the following considerations:<list list-type="bullet"><list-item><p>The vitamin A compliance rate should be the same in each group since patients have been randomly assigned.</p></list-item><list-item><p>The mortality rate in the potential noncompliers in the control group should be the same as in the noncompliers assigned vitamin A, since in both arms the noncompliers are not receiving vitamin A.</p></list-item></list>With these assumptions, the missing data in <xref ref-type="table" rid="table1-2168479013486270">Table 1</xref> can be estimated from the observed data. First, 9675 of 12,094 patients assigned vitamin A are taking it, which results in a compliance rate of about 0.8. Under the first assumption, 11,588 × 0.8 ≈ 9270.2 patients assigned to no treatment would take vitamin A if assigned to it, while 11,588 – 9270.2 = 2317.8 are expected not to take it despite assignment. Assuming an identical death rate in patients not taking vitamin A when assigned to it would result in 2317.8 × 0.01406 ≈ 32.6 expected deaths in control patients who would not take vitamin A if it were assigned to them and, consequently, 74 – 32.6 = 41.4 expected deaths in control patients who would take vitamin A if it were assigned. This results in a death rate of 41.4/9270.2 = 0.0045 in the latter patient group.</p><p>These results are shown in <xref ref-type="table" rid="table2-2168479013486270">Table 2</xref>. The relative risk of the compliers assigned vitamin A and the potential vitamin A compliers from the control group is then 0.12/0.45 = 0.27, which is between the per-protocol result and the ITT result. Note that the estimation of the variance of this relative risk has to account for the additional uncertainty from the estimation process of the missing information. A proposal for the latter is provided by Sommer and Zeger.<sup><xref ref-type="bibr" rid="bibr3-2168479013486270">3</xref></sup></p><p>The thoughts behind the example given above have been somewhat formalized by Sheiner and Rubin,<sup><xref ref-type="bibr" rid="bibr4-2168479013486270">4</xref></sup> who considered a clinical trial with 2 treatments, control (C) and experimental (E), such that patients are randomly assigned C or E. It is assumed that all patients assigned C are fully compliant (ie, always take C), while the noncompliant patients assigned E take C instead. Outcome is known for all patients regardless of compliance (ie, no missing data). An ITT analysis would consider all patients, while a per-protocol analysis would compare the compliers assigned E with all patients assigned C, thereby not comparing like with like.</p><p>The appropriate estimator of efficacy would compare the effect in compliers assigned E (denoted by η<sub>comp</sub>) with the effect in those patients assigned C, who would have complied to E had they been assigned E (θ<sub>comp</sub>):</p><disp-formula id="disp-formula1-2168479013486270"><mml:math id="mml-disp2-2168479013486270"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">=</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mo>η</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">−</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mo>θ</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">p</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math><graphic alternate-form-of="disp-formula1-2168479013486270" xlink:href="10.1177_2168479013486270-eq1.tif"/></disp-formula><p>If π<sub>C</sub> and π<sub>E</sub> denote the compliance rates under C and E, respectively, if E had been assigned, the effect is θ = π<sub>C</sub>θ<sub>comp</sub> + (1 – π<sub>C</sub>)θ<sub>ncomp</sub> for the control group and η = π<sub>E</sub>η<sub>comp</sub> + (1 – π<sub>E</sub>)η<sub>ncomp</sub> under experimental treatment.</p><p>Because patients have been randomly assigned to C or E, it can be assumed that π<sub>C</sub> = π<sub>E</sub>. Since noncompliers in both groups receive C, θ<sub>ncomp</sub> = η<sub>ncomp</sub> is a plausible assumption. Putting all pieces together gives η – θ = π<sub>E</sub>[η<sub>comp</sub> – θ<sub>comp</sub>] or<disp-formula id="disp-formula2-2168479013486270"><mml:math id="mml-disp4-2168479013486270"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>η</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="false">−</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>θ</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mo>π</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math><graphic alternate-form-of="disp-formula2-2168479013486270" xlink:href="10.1177_2168479013486270-eq2.tif"/></disp-formula></p><p>Hence a proper estimator of the efficacy of E relative to C can be obtained from the ITT estimators of effectiveness divided by the compliance rate under E.</p></sec><sec id="section5-2168479013486270"><title>Estimators of Efficacy Under Lack of Compliance and Missingness</title><p>So far we have assumed that all outcomes are observed regardless of compliance (ie, that all patients are followed up until the planned end of the trial and there are no missing data). In practice, however, not all data will be observed. The question is therefore how to address lack of compliance and missing data in the analysis of a clinical study.</p><p>A recent example of how to address this issue was provided by Kenward and Rosenkranz.<sup><xref ref-type="bibr" rid="bibr9-2168479013486270">9</xref></sup> They describe a reanalysis of a safety study in patients with congestive heart failure (CHF). The primary goal was to investigate the effect of 1 year of treatment with an experimental drug on cardiac function, determined by echocardiography. An echocardiogram was to be taken at baseline and week 52 (end of study). Patients who discontinued their treatment before the full year were asked to undergo an echocardiogram at the time of discontinuation. Some data will be missing because of patients’ refusal to undergo the postbaseline measurement procedure, whether at the time of discontinuation or at the end of the study. The potential outcomes of this study are displayed in <xref ref-type="table" rid="table3-2168479013486270">Table 3</xref>.</p><table-wrap id="table3-2168479013486270" position="float"><label>Table 3.</label><caption><p>Potential outcomes of the congestive heart failure study.</p></caption><graphic alternate-form-of="table3-2168479013486270" xlink:href="10.1177_2168479013486270-table3.tif"/><table><thead><tr><th>Observation Time Point</th><th>Echocardiogram Performed</th><th>Outcome</th></tr></thead><tbody><tr><td rowspan="2">At end of study (compliant)</td><td>No</td><td>Missing</td></tr><tr><td>Yes</td><td>Measurement</td></tr><tr><td rowspan="2">Before end of study (noncompliant)</td><td>No</td><td>Missing</td></tr><tr><td>Yes</td><td>Measurement</td></tr></tbody></table><table-wrap-foot><fn id="table-fn2-2168479013486270"><p>Data from Kenward and Rosenkranz.<sup><xref ref-type="bibr" rid="bibr9-2168479013486270">9</xref></sup></p></fn></table-wrap-foot></table-wrap><p>The proposed analysis model of this study contains a primary variable of interest <italic>Y</italic>, a response indicator <italic>R</italic> with <italic>R = </italic>1 if <italic>Y</italic> is observed and zero otherwise, the observation time <italic>T</italic> = min(<italic>T</italic><sub>0</sub>, 1 year), a treatment indicator <italic>z</italic>, and a random patient effect <italic>U</italic>. Let <italic>p</italic>(<italic>t, z, u</italic>) = Pr[<italic>R =</italic> 1|<italic>t, z, u</italic>]. The distributional assumptions were as follows:<disp-formula id="disp-formula3-2168479013486270"><mml:math id="mml-disp6-2168479013486270"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow><mml:mtext> </mml:mtext><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi>z</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">~</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mi mathvariant="italic">μ</mml:mi></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mo>τ</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mi>T</mml:mi></mml:msub><mml:mi>u</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">θ</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msub><mml:mi>z</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">σ</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math><graphic alternate-form-of="disp-formula3-2168479013486270" xlink:href="10.1177_2168479013486270-eq3.tif"/></disp-formula><disp-formula id="disp-formula4-2168479013486270"><mml:math id="mml-disp8-2168479013486270"><mml:mi>Y</mml:mi><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>z</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">~</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">μ</mml:mi></mml:mrow><mml:mi>Y</mml:mi></mml:msub><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mo>τ</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mi>Y</mml:mi></mml:msub><mml:mi>u</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">θ</mml:mi></mml:mrow><mml:mi>Y</mml:mi></mml:msub><mml:mi>z</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">γ</mml:mi></mml:mrow><mml:mi>Y</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow><mml:mi>t</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">σ</mml:mi></mml:mrow><mml:mi>Y</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math><graphic alternate-form-of="disp-formula4-2168479013486270" xlink:href="10.1177_2168479013486270-eq4.tif"/></disp-formula><disp-formula id="disp-formula5-2168479013486270"><mml:math id="mml-disp10-2168479013486270"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mrow><mml:mfenced close="}" open="{"><mml:mrow><mml:mi>p</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi>t</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>z</mml:mi><mml:mo stretchy="false">,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo stretchy="false">=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">μ</mml:mi></mml:mrow><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mrow><mml:mo>τ</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mi>R</mml:mi></mml:msub><mml:mi>u</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">θ</mml:mi></mml:mrow><mml:mi>R</mml:mi></mml:msub><mml:mi>z</mml:mi><mml:mo stretchy="false">+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">γ</mml:mi></mml:mrow><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:mrow></mml:mrow><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:math><graphic alternate-form-of="disp-formula5-2168479013486270" xlink:href="10.1177_2168479013486270-eq5.tif"/></disp-formula></p><p>The model above is a shared parameter model that accounts for missing data under the assumption of missing at random conditional on <italic>U</italic>. The parameter of most interest is θ<italic><sub>Y</sub></italic>, which describes the effect of treatment on the outcome variable <italic>Y</italic>. The assumptions made for the distributions of <italic>Y</italic>, <italic>R</italic>, and <italic>T</italic> led to likelihood containing 13 parameters that were estimated by use of PROC NLMIXED of SAS. Explanations of the model assumptions are contained in Kenward and Rosenkranz.<sup>9</sup> An analysis of covariance (ANCOVA) of <italic>Y</italic> results in a <italic>P</italic> value of .99 while the analysis based on the model above yielded <italic>P</italic> = .8 for the comparison between the groups. This example was provided to highlight the additional amount of modeling that may be needed when more complex compliance issues than those discussed earlier are to be accounted for.</p></sec></sec><sec id="section6-2168479013486270"><title>Discussion</title><p>In this article we argue that the definitions of FAS and PPS and proposed uses of ITT and per-protocol analyses as described in ICH E9 can be misleading. As explained earlier, the results of an ITT analysis may be less generalizable to patients treated outside of clinical trials than often suggested. Ware and Hamel<sup><xref ref-type="bibr" rid="bibr11-2168479013486270">11</xref></sup> point out that the enrolled populations and patient management approach in clinical trials do not reflect the complexity and diversity of actual clinical practice. Consequently, the effectiveness of an intervention estimated from clinical trials has to be interpreted with caution when the results are to be applied to real-world situations. However, we have shown that the per-protocol analysis misses the goal of estimating efficacy since it compares populations under different compliance challenges without adjusting for this. Hence, the important concepts of efficacy and effectiveness are unsatisfactorily supported by per-protocol and ITT analyses, respectively.</p><p>We have referred to 2 simple examples from the literature: one to illustrate the impact of the misconception described above and the second to point to a situation where the appropriate estimator of efficacy is the inverse probability of compliance reweighted ITT estimator and not the per-protocol estimator. The important role of randomization became obvious.</p><p>The degree of modeling required may increase with the complexity of noncompliance that is to be accounted for in the analysis. When missing data come into play, as they usually do in clinical trials, the situation gets more complex and the amount of modeling may further increase as illustrated in the third example. Reaching agreement on plausible models in a given situation may become an area for discussion at health authority consultations. The simple (or simple-appearing) solution like a strict ITT analysis generally does not address the issue: “[For symptomatic] studies it is strongly expected that there could be a prompt loss of a drug’s effect after it is discontinued; therefore the inclusion of data from subjects who have discontinued the drug would introduce a bias against the drug when ITT analysis is carried out.”<sup><xref ref-type="bibr" rid="bibr12-2168479013486270">12</xref></sup></p><p>The preceding sections have provided some proposals of ways to use data captured for all patients in a meaningful way in the analysis under lack of compliance and in the presence of missing data. Similar proposals could be applied to clinical trials of any phase and would also be helpful in settling the discussion about the most appropriate analysis set for noninferiority trials. In any case, the question of what constitutes the most appropriate estimands of a treatment effect (benefit or harm) has to be determined in advance to design the study appropriately. Whether a single treatment effect estimator can be identified<sup><xref ref-type="bibr" rid="bibr9-2168479013486270">9</xref></sup> or a series of estimators for different degrees of compliance has to be considered<sup><xref ref-type="bibr" rid="bibr6-2168479013486270">6</xref></sup> may become a major topic of discussion going forward. The latter proposal can deliver an estimate of efficacy and provide a picture of effectiveness as a function of compliance under the circumstances of the trial at hand. Whatever approach is taken in a specific setting, one of the recommendations of the US National Academy of Sciences report on missing data is essential: “Investigators, sponsors and regulators should design clinical trials consistent with the goal of maximizing the number of participants who are maintained on the protocol-specified intervention until the outcome data are collected.”<sup><xref ref-type="bibr" rid="bibr13-2168479013486270">13</xref></sup></p></sec></body><back><ack><title>Acknowledgment</title><p>The author thanks an anonymous reviewer for the thoughtful and stimulating comments that contributed substantially to improving the presentation and sharpening the message of the paper.</p></ack><fn-group><fn fn-type="conflict" id="fn1-2168479013486270"><label>Declaration of Conflicting Interests</label><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure" id="fn2-2168479013486270"><label>Funding</label><p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2168479013486270"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiens</surname><given-names>BL</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name></person-group>. <article-title>The role of intention-to-treat analysis in non-inferiority trials</article-title>. <source>Clin Trials</source>. <year>2007</year>;<volume>4</volume>:<fpage>286</fpage>–<lpage>291</lpage>.</citation></ref><ref id="bibr2-2168479013486270"><label>2</label><citation citation-type="web"><collab collab-type="author">International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use</collab>. <article-title>Statistical Principles for Clinical Trials E9</article-title>. <year>1998</year>. <ext-link ext-link-type="uri" xlink:href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf</ext-link>.</citation></ref><ref id="bibr3-2168479013486270"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>A</given-names></name><name><surname>Zeger</surname><given-names>SL</given-names></name></person-group>. <article-title>On estimating efficacy from clinical trials</article-title>. <source>Stat Med</source>. <year>1991</year>;<volume>10</volume>:<fpage>45</fpage>–<lpage>52</lpage>.</citation></ref><ref id="bibr4-2168479013486270"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sheiner</surname><given-names>LB</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>. <article-title>Intention-to-treat analysis and the goals of clinical trials</article-title>. <source>Clin Pharmacol Ther</source>. <year>1995</year>;<volume>57</volume>:<fpage>6</fpage>–<lpage>15</lpage>.</citation></ref><ref id="bibr5-2168479013486270"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frangakis</surname><given-names>CE</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>. <article-title>Principal stratification in causal inference</article-title>. <source>Biometrics</source>. <year>2002</year>;<volume>58</volume>:<fpage>21</fpage>–<lpage>29</lpage>.</citation></ref><ref id="bibr6-2168479013486270"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>. <article-title>Principal stratification for causal inference with extended partial compliance</article-title>. <source>J Am Stat Assoc</source>. <year>2008</year>;<volume>103</volume>:<fpage>101</fpage>–<lpage>111</lpage>.</citation></ref><ref id="bibr7-2168479013486270"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname><given-names>JM.</given-names></name></person-group> <article-title>Correcting for non-compliance in randomized trials using structural nested mean models</article-title>. <source>Commun Stat Theory Methods</source>. <year>1994</year>;<volume>23</volume>:<fpage>2379</fpage>–<lpage>2412</lpage>.</citation></ref><ref id="bibr8-2168479013486270"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer-Lapp</surname><given-names>K</given-names></name><name><surname>Goetghebeur</surname><given-names>E</given-names></name></person-group>. <article-title>Practical properties of some structural mean analyses of the effect of compliance in randomized trials</article-title>. <source>Control Clin Trials</source>. <year>1999</year>;<volume>20</volume>:<fpage>531</fpage>–<lpage>546</lpage>.</citation></ref><ref id="bibr9-2168479013486270"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kenward</surname><given-names>MG</given-names></name><name><surname>Rosenkranz</surname><given-names>GK</given-names></name></person-group>. <article-title>Joint modeling of outcome, observation time and missingness</article-title>. <source>J Biopharm Stat</source>. <year>2011</year>;<volume>21</volume>:<fpage>252</fpage>–<lpage>262</lpage>.</citation></ref><ref id="bibr10-2168479013486270"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenkranz</surname><given-names>GK</given-names></name></person-group>. <article-title>The impact of randomization on the analysis of clinical trials</article-title>. <source>Stat Med</source>. <year>2011</year>;<volume>30</volume>:<fpage>3075</fpage>–<lpage>3487</lpage>.</citation></ref><ref id="bibr11-2168479013486270"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JH</given-names></name><name><surname>Hamel</surname><given-names>MB</given-names></name></person-group>. <article-title>Pragmatic trials—guides to better patient care?</article-title> <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>1685</fpage>–<lpage>1687</lpage>.</citation></ref><ref id="bibr12-2168479013486270"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O’Neill</surname><given-names>RT</given-names></name><name><surname>Temple</surname><given-names>R</given-names></name></person-group>. <article-title>The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it</article-title>. <source>Clin Pharmacol Ther</source>. <year>2012</year>;<volume>91</volume>:<fpage>550</fpage>–<lpage>554</lpage>.</citation></ref><ref id="bibr13-2168479013486270"><label>13</label><citation citation-type="book"><collab collab-type="author">The Panel on Handling Missing Data in Clinical Trials; National Research Council</collab>. <source>The Prevention and Treatment of Missing Data in Clinical Trials</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://www.nap.edu/catalog.php?record_id=12955">http://www.nap.edu/catalog.php?record_id=12955</ext-link>.</citation></ref></ref-list></back></article>